<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34209129</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>13</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1<sup>G93A</sup> Transgenic Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7066</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22137066</ELocationID><Abstract><AbstractText>Neuroinflammation is a pathological hallmark of several neurodegenerative disorders and plays a key role in the pathogenesis of amyotrophic lateral sclerosis (ALS). It has been implicated as driver of disease progression and is observed in ALS patients, as well as in the transgenic SOD1<sup>G93A</sup> mouse model. Here, we explore and validate the therapeutic potential of the d-enantiomeric peptide RD2RD2 upon oral administration in SOD1<sup>G93A</sup> mice. Transgenic mice were treated daily with RD2RD2 or placebo for 10 weeks and phenotype progression was followed with several behavioural tests. At the end of the study, plasma cytokine levels and glia cell markers in brain and spinal cord were analysed. Treatment resulted in a significantly increased performance in behavioural and motor coordination tests and a decelerated neurodegenerative phenotype in RD2RD2-treated SOD1<sup>G93A</sup> mice. Additionally, we observed retardation of the average disease onset. Treatment of SOD1<sup>G93A</sup> mice led to significant reduction in glial cell activation and a rescue of neurons. Analysis of plasma revealed normalisation of several cytokines in samples of RD2RD2-treated SOD1<sup>G93A</sup> mice towards the levels of non-transgenic mice. In conclusion, these findings qualify RD2RD2 to be considered for further development and testing towards a disease modifying ALS treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaffrath</LastName><ForeName>Anja</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3084-3557</Identifier><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gering</LastName><ForeName>Ian</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-0965-3908</Identifier><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartwig</LastName><ForeName>Sonja</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5225-6804</Identifier><AffiliationInfo><Affiliation>Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Diabetes Research, Partner D&#xfc;sseldorf, 85764 M&#xfc;nchen-Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehr</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5575-4315</Identifier><AffiliationInfo><Affiliation>Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Diabetes Research, Partner D&#xfc;sseldorf, 85764 M&#xfc;nchen-Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>N Jon</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0002-8151-6169</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine 11, INM-11, JARA, Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>JARA-Brain-Translational Medicine, 52062 Aachen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, RWTH Aachen University, 52062 Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langen</LastName><ForeName>Karl-Josef</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0003-1101-5075</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, RWTH Aachen University, 52062 Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willbold</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0065-7366</Identifier><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutzsche</LastName><ForeName>Janine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0271-7390</Identifier><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willuweit</LastName><ForeName>Antje</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6725-0755</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20-64-46027</GrantID><Agency>Russian Science Foundation</Agency><Country/></Grant><Grant><GrantID>Technology Transfer Fund</GrantID><Agency>Forschungszentrum J&#xfc;lich</Agency><Country/></Grant><Grant><GrantID>Portfolio Drug Research</GrantID><Agency>Impuls und Vernetzungs-Fonds der Helmholtzgemeinschaft</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SOD1G93A</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">behaviour</Keyword><Keyword MajorTopicYN="N">d-enantiomeric peptide</Keyword><Keyword MajorTopicYN="N">motor coordination</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">plasma cytokines</Keyword></KeywordList><CoiStatement>D.W. is co-inventor of patents covering the composition of matter of RD2RD2. D.W. and A.W. are co-founders and shareholders of the company &#x201c;Priavoid GmbH, D&#xfc;sseldorf, Germany&#x201d;, which is planning to further develop RD2RD2. All other authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>1</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34209129</ArticleId><ArticleId IdType="pmc">PMC8269060</ArticleId><ArticleId IdType="doi">10.3390/ijms22137066</ArticleId><ArticleId IdType="pii">ijms22137066</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Magnus T., Beck M., Giess R., Puls I., Naumann M., Toyka K. Disease progression in amyotrophic lateral sclerosis: Predictors of survival. Muscle Nerve. 2002;25:709&#x2013;714. doi: 10.1002/mus.10090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10090</ArticleId><ArticleId IdType="pubmed">11994965</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott C., Shaw P. Diagnosis and management of motor neurone disease. BMJ. 2008;336:658&#x2013;662. doi: 10.1136/bmj.39493.511759.BE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39493.511759.BE</ArticleId><ArticleId IdType="pmc">PMC2270983</ArticleId><ArticleId IdType="pubmed">18356234</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S., Murn M., Choi P.J. Respiratory Failure in Amyotrophic Lateral Sclerosis. Chest. 2019;155:401&#x2013;408. doi: 10.1016/j.chest.2018.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Chio A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Cleveland D.W. Decoding ALS: From genes to mechanism. Nat. Cell Biol. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M., Sims K.B., Xin W.W., Kiely R., O&#x2019;Neill G., Ravits J., Pioro E., Harati Y., Brower R.D., Levine J.S., et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: A decade of discoveries, defects and disputes. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2003;4:62&#x2013;73. doi: 10.1080/14660820310011700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310011700</ArticleId><ArticleId IdType="pubmed">14506936</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr. Neurol. Neurosci. Rep. 2006;6:37&#x2013;46. doi: 10.1007/s11910-996-0008-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-996-0008-9</ArticleId><ArticleId IdType="pubmed">16469270</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P.C., Hentati A., Donaldson D.H., Goto J., O&#x2019;Regan J.P., Deng H.-X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., McKenna-Yasek D., Sapp P.E., Chin W., Geller B., Hayden D.L., Schoenfeld D.A., Hosler B.A., Horvitz H.R., Brown R.H. Epidemiology of mutations in superoxide dismutase in amyotrophic lateal sclerosis. Ann. Neurol. 1997;41:210&#x2013;221. doi: 10.1002/ana.410410212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410212</ArticleId><ArticleId IdType="pubmed">9029070</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado L., D&#x2019;Alfonso S., Bergamaschi L., Testa L., Leone M., Nasuelli N., Momigliano-Richiardi P., Mazzini L. SOD1 gene mutations in Italian patients with Sporadic Amyotrophic Lateral Sclerosis (ALS) Neuromuscul. Disord. 2006;16:800&#x2013;804. doi: 10.1016/j.nmd.2006.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2006.07.004</ArticleId><ArticleId IdType="pubmed">16952453</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon M.-J., Baek W., Ki C.-S., Kim H.Y., Koh S.-H., Kim J.-W., Kim S.H. Screening of the SOD1, FUS, TARDBP, ANG, and OPTN mutations in Korean patients with familial and sporadic ALS. Neurobiol. Aging. 2012;33:1017.e17&#x2013;1017.e23. doi: 10.1016/j.neurobiolaging.2011.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.12.003</ArticleId><ArticleId IdType="pubmed">22244934</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P., Joyce P.I., Fisher E.M., Greensmith L. Rodent models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2013;1832:1421&#x2013;1436. doi: 10.1016/j.bbadis.2013.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2013.03.012</ArticleId><ArticleId IdType="pubmed">23524377</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Rodent Models of Amyotrophic Lateral Sclerosis. Curr. Protoc. Pharmacol. 2015;69:5.67.1&#x2013;5.67.21. doi: 10.1002/0471141755.ph0567s69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V., Valdmanis P.N., Gould P.V., Julien J.-P., Dupr&#xe9; N. From animal models to human disease: A genetic approach for personalized medicine in ALS. Acta Neuropathol. Commun. 2016;4:70. doi: 10.1186/s40478-016-0340-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId><ArticleId IdType="pmc">PMC4940869</ArticleId><ArticleId IdType="pubmed">27400686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz C. Mouse models of ALS: Past, present and future. Brain Res. 2018;1693:1&#x2013;10. doi: 10.1016/j.brainres.2018.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.03.024</ArticleId><ArticleId IdType="pubmed">29577886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu A.Y., Zhai P., Canto M.C.D., Peters T.M., Kwon Y.W., Prattis S.M., Gurney M.E. Age-Dependent Penetrance of Disease in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis. Mol. Cell. Neurosci. 1995;6:349&#x2013;362. doi: 10.1006/mcne.1995.1027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.1995.1027</ArticleId><ArticleId IdType="pubmed">8846004</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander G.M., Erwin K.L., Byers N., Deitch J.S., Augelli B.J., Blankenhorn E.P., Heiman-Patterson T.D. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Mol. Brain Res. 2004;130:7&#x2013;15. doi: 10.1016/j.molbrainres.2004.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molbrainres.2004.07.002</ArticleId><ArticleId IdType="pubmed">15519671</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcuzzo S., Zucca I., Mastropietro A., de Rosbo N.K., Cavalcante P., Tartari S., Bonanno S., Preite L., Mantegazza R., Bernasconi P. Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: A longitudinal MRI study. Exp. Neurol. 2011;231:30&#x2013;37. doi: 10.1016/j.expneurol.2011.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.05.007</ArticleId><ArticleId IdType="pubmed">21620832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrante R.J., Browne S.E., Shinobu L.A., Bowling A.C., Baik M.J., MacGarvey U., Kowall N.W., Brown R.H., Jr., Beal M.F. Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis. J. Neurochem. 1997;69:2064&#x2013;2074. doi: 10.1046/j.1471-4159.1997.69052064.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69052064.x</ArticleId><ArticleId IdType="pubmed">9349552</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara T., Ishigaki S., Yamamoto M., Liang Y., Jun Niwa I., Takeuchi H., Doyu M., Sobue G. Differential expression of inflammation-and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 2002;80:158&#x2013;167. doi: 10.1046/j.0022-3042.2001.00683.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0022-3042.2001.00683.x</ArticleId><ArticleId IdType="pubmed">11796754</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253&#x2013;263. doi: 10.1016/S1474-4422(11)70015-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Zhao W., Liao B., Kano O., Wang J., Huang A., Appel S.H., Henkel J.S. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav. Immun. 2011;25:1025&#x2013;1035. doi: 10.1016/j.bbi.2010.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.008</ArticleId><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Henderson R.D. The Role of Immune and Inflammatory Mechanisms in ALS. Curr. Mol. Med. 2011;11:246&#x2013;254. doi: 10.2174/156652411795243450.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411795243450</ArticleId><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans M., Couch Y., Sibson N., Turner M. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 2013;53:34&#x2013;41. doi: 10.1016/j.mcn.2012.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2012.10.008</ArticleId><ArticleId IdType="pubmed">23110760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall E.D., Oostveen J.A., Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998;23:249&#x2013;256. doi: 10.1002/(SICI)1098-1136(199807)23:3&lt;249::AID-GLIA7&gt;3.0.CO;2-#.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-1136(199807)23:3&lt;249::AID-GLIA7&gt;3.0.CO;2-#</ArticleId><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips A.M., Hester M.E., Miranda C., Meyer K., Braun L., Frakes A., Song S., Likhite S., Murtha M.J., Foust K.D., et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011;29:824&#x2013;828. doi: 10.1038/nbt.1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso M.C., Corvino V., Marchese E., Serrano A., Michetti F., D&#x2019;Ambrosi N. The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches. Front. Aging Neurosci. 2017;9:242. doi: 10.3389/fnagi.2017.00242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00242</ArticleId><ArticleId IdType="pmc">PMC5524666</ArticleId><ArticleId IdType="pubmed">28790913</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott J.L. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Mol. Brain Res. 2001;95:172&#x2013;178. doi: 10.1016/S0169-328X(01)00242-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(01)00242-X</ArticleId><ArticleId IdType="pubmed">11687290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyachandran A., Mertens B., McKissick E.A., Mitchell C.S. Type I vs. Type II cytokine levels as a function of SOD1 G93A mouse amyotrophic lateral sclerosis disease progression. Front. Cell. Neurosci. 2015;9:462. doi: 10.3389/fncel.2015.00462.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00462</ArticleId><ArticleId IdType="pmc">PMC4664727</ArticleId><ArticleId IdType="pubmed">26648846</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Appel S.H. Introduction to supplement: The current status of treatment for ALS. Amyotroph. Lateral Scler. Front. Degener. 2017;18:1&#x2013;4. doi: 10.1080/21678421.2017.1361447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361447</ArticleId><ArticleId IdType="pubmed">28872909</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S., Couratier P., Julian A., Corcia P., Le Masson G. Current view and perspectives in amyotrophic lateral sclerosis. Neural Regen. Res. 2017;12:181&#x2013;184. doi: 10.4103/1673-5374.200794.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.200794</ArticleId><ArticleId IdType="pmc">PMC5361492</ArticleId><ArticleId IdType="pubmed">28400790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon P.H. Amyotrophic lateral sclerosis. CNS Drugs. 2011;25:1&#x2013;15. doi: 10.2165/11586000-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11586000-000000000-00000</ArticleId><ArticleId IdType="pubmed">21128691</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., Ludolph A.C., Huebers A. Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis. Ther. Adv. Neurol. Disord. 2017;11 doi: 10.1177/1756285617734734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285617734734</ArticleId><ArticleId IdType="pmc">PMC5784546</ArticleId><ArticleId IdType="pubmed">29399045</ArticleId></ArticleIdList></Reference><Reference><Citation>Leithold L.H., Jiang N., Post J., Niemietz N., Schartmann E., Ziehm T., Kutzsche J., Shah N.J., Breitkreutz J., Langen K.-J., et al. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer&#x2019;s disease. Eur. J. Pharm. Sci. 2016;89:31&#x2013;38. doi: 10.1016/j.ejps.2016.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2016.04.016</ArticleId><ArticleId IdType="pubmed">27086111</ArticleId></ArticleIdList></Reference><Reference><Citation>Schartmann E., Schemmert S., Niemietz N., Honold D., Ziehm T., Tusche M., Elfgen A., Gering I., Brener O., Shah N.J., et al. In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer&#x2019;s Disease. J. Alzheimer&#x2019;s Dis. 2018;64:859&#x2013;873. doi: 10.3233/JAD-180165.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180165</ArticleId><ArticleId IdType="pmc">PMC6218115</ArticleId><ArticleId IdType="pubmed">29966196</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfgen A., Hupert M., Bochinsky K., Tusche M., Martin E.G.D.S.R., Gering I., Sacchi S., Pollegioni L., Huesgen P.F., Hartmann R., et al. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-&#x3b2; oligomers. Sci. Rep. 2019;9:5715. doi: 10.1038/s41598-019-41993-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41993-6</ArticleId><ArticleId IdType="pmc">PMC6450887</ArticleId><ArticleId IdType="pubmed">30952881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzsche J., J&#xfc;rgens D., Willuweit A., Adermann K., Fuchs C., Simons S., Windisch M., H&#xfc;mpel M., Rossberg W., Wolzt M., et al. Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study. Alzheimer&#x2019;s Dementia Transl. Res. Clin. Interv. 2020;6:e12001. doi: 10.1002/trc2.12001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12001</ArticleId><ArticleId IdType="pmc">PMC7087413</ArticleId><ArticleId IdType="pubmed">32211506</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Groen T., Schemmert S., Brener O., Gremer L., Ziehm T., Tusche M., Nagel-Steger L., Kadish I., Schartmann E., Elfgen A., et al. The A&#x3b2; oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Sci. Rep. 2017;7:16275. doi: 10.1038/s41598-017-16565-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16565-1</ArticleId><ArticleId IdType="pmc">PMC5701182</ArticleId><ArticleId IdType="pubmed">29176708</ArticleId></ArticleIdList></Reference><Reference><Citation>Schemmert S., Schartmann E., Zafiu C., Kass B., Hartwig S., Lehr S., Bannach O., Langen K.-J., Shah N.J., Kutzsche J., et al. A&#x3b2; Oligomer Elimination Restores Cognition in Transgenic Alzheimer&#x2019;s Mice with Full-blown Pathology. Mol. Neurobiol. 2019;56:2211&#x2013;2223. doi: 10.1007/s12035-018-1209-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1209-3</ArticleId><ArticleId IdType="pmc">PMC6394605</ArticleId><ArticleId IdType="pubmed">30003517</ArticleId></ArticleIdList></Reference><Reference><Citation>Schemmert S., Schartmann E., Honold D., Zafiu C., Ziehm T., Langen K.-J., Shah N.J., Kutzsche J., Willuweit A., Willbold D. Deceleration of the neurodegenerative phenotype in pyroglutamate-A&#x3b2; accumulating transgenic mice by oral treatment with the A&#x3b2; oligomer eliminating compound RD2. Neurobiol. Dis. 2019;124:36&#x2013;45. doi: 10.1016/j.nbd.2018.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.10.021</ArticleId><ArticleId IdType="pubmed">30391539</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Loschwitz J., Strodel B., Nagel-Steger L., Willbold D. Interference with Amyloid-&#x3b2; Nucleation by Transient Ligand Interaction. Molecules. 2019;24:2129. doi: 10.3390/molecules24112129.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24112129</ArticleId><ArticleId IdType="pmc">PMC6600523</ArticleId><ArticleId IdType="pubmed">31195746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzsche J., Schemmert S., Tusche M., Neddens J., Rabl R., J&#xfc;rgens D., Brener O., Willuweit A., Hutter-Paier B., Willbold D. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer&#x2019;s Disease. Molecules. 2017;22:1693. doi: 10.3390/molecules22101693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22101693</ArticleId><ArticleId IdType="pmc">PMC6151452</ArticleId><ArticleId IdType="pubmed">28994710</ArticleId></ArticleIdList></Reference><Reference><Citation>Post J., Kogel V., Schaffrath A., Lohmann P., Shah N.J., Langen K.J., Willbold D., Willuweit A., Kutzsche J. A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model. Molecules. 2021;26:1590. doi: 10.3390/molecules26061590.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26061590</ArticleId><ArticleId IdType="pmc">PMC7999518</ArticleId><ArticleId IdType="pubmed">33805709</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead R.J., Bennett E.J., Kennerley A.J., Sharp P., Sunyach C., Kasher P., Berwick J., Pettmann B., Battaglia G., Azzouz M., et al. Optimised and Rapid Pre-clinical Screening in the SOD1G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (ALS) PLoS ONE. 2011;6:e23244. doi: 10.1371/journal.pone.0023244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023244</ArticleId><ArticleId IdType="pmc">PMC3158065</ArticleId><ArticleId IdType="pubmed">21876739</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci M., Spalloni A., Bartalucci A., Cantafora E., Fulceri F., Nutini M., Longone P., Paparelli A., Fornai F. A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium. Neurobiol. Dis. 2010;37:370&#x2013;383. doi: 10.1016/j.nbd.2009.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.10.017</ArticleId><ArticleId IdType="pubmed">19874893</ArticleId></ArticleIdList></Reference><Reference><Citation>Dibaj P., Zsch&#xfc;ntzsch J., Steffens H., Scheffel J., G&#xf6;ricke B., Weishaupt J.H., Le Meur K., Kirchhoff F., Hanisch U.-K., Schomburg E.D., et al. Influence of Methylene Blue on Microglia-Induced Inflammation and Motor Neuron Degeneration in the SOD1G93A Model for ALS. PLoS ONE. 2012;7:e43963. doi: 10.1371/journal.pone.0043963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0043963</ArticleId><ArticleId IdType="pmc">PMC3428282</ArticleId><ArticleId IdType="pubmed">22952827</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnick N.D., Griffey C.J., Guarnieri P., Gerbino V., Wang X., Piersaint J.A., Tapia J.C., Rich M.M., Maniatis T. Distinct roles for motor neuron autophagy early and late in the SOD1G93A mouse model of ALS. Proc. Natl. Acad. Sci. USA. 2017;114:E8294&#x2013;E8303. doi: 10.1073/pnas.1704294114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1704294114</ArticleId><ArticleId IdType="pmc">PMC5625902</ArticleId><ArticleId IdType="pubmed">28904095</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara J.H., Gen&#xe7; B., Stanford M.J., Pytel P., Roos R.P., Weintraub S., Mesulam M.M., Bigio E.H., Miller R.J., &#xd6;zdinler P.H. Evidence for an early innate immune response in the motor cortex of ALS. J. Neuroinflamm. 2017;14:129. doi: 10.1186/s12974-017-0896-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0896-4</ArticleId><ArticleId IdType="pmc">PMC5485686</ArticleId><ArticleId IdType="pubmed">28651542</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D.W., Rothstein J.D. From charcot to lou gehrig: Deciphering selective motor neuron death in als. Nat. Rev. Neurosci. 2001;2:806&#x2013;819. doi: 10.1038/35097565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35097565</ArticleId><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur K.C., Calvo A., Price T.R., Geiger J.T., Chi&#xf2; A.C.A., Traynor K.C.A.B.J. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun. 2016;7:12408. doi: 10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley M.E., Baloh R.H. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137:715&#x2013;730. doi: 10.1007/s00401-018-1933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia. Science. 2006;312:1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K., Abdel-Moaty H., Hunter J., Mhatre M., Mou S., Nguyen K., Potapova T., Pye Q.N., Qi M., Rice H., et al. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J. Neuroinflamm. 2006;3:2. doi: 10.1186/1742-2094-3-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-2</ArticleId><ArticleId IdType="pmc">PMC1360663</ArticleId><ArticleId IdType="pubmed">16436205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten K.G., Beers D.R., Zhao W., Appel S.H. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12:364&#x2013;375. doi: 10.1007/s13311-014-0329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher B., Spath B.B.S., Goverman J. Cytokine networks in neuroinflammation. Nat. Rev. Immunol. 2017;17:49&#x2013;59. doi: 10.1038/nri.2016.123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.123</ArticleId><ArticleId IdType="pubmed">27916979</ArticleId></ArticleIdList></Reference><Reference><Citation>Mammana S., Fagone P., Cavalli E., Basile M.S., Petralia M.C., Nicoletti F., Bramanti P., Mazzon E. The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer&#x2019;s Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. Int. J. Mol. Sci. 2018;19:831. doi: 10.3390/ijms19030831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19030831</ArticleId><ArticleId IdType="pmc">PMC5877692</ArticleId><ArticleId IdType="pubmed">29533975</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J.S., Beers D.R., Zhao W., Appel S.H. Microglia in ALS: The Good, The Bad, and The Resting. J. Neuroimmune Pharmacol. 2009;4:389&#x2013;398. doi: 10.1007/s11481-009-9171-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-009-9171-5</ArticleId><ArticleId IdType="pubmed">19731042</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Appel S.H. Immune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis. J. Neuroimmune Pharmacol. 2013;8:888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller A.F., Gravel M., Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp. Neurol. 2011;228:69&#x2013;79. doi: 10.1016/j.expneurol.2010.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.12.010</ArticleId><ArticleId IdType="pubmed">21168408</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P., Julien J.-P., Kriz J. Early-Stage Treatment with Withaferin A Reduces Levels of Misfolded Superoxide Dismutase 1 and Extends Lifespan in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12:217&#x2013;233. doi: 10.1007/s13311-014-0311-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0311-0</ArticleId><ArticleId IdType="pmc">PMC4322065</ArticleId><ArticleId IdType="pubmed">25404049</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Fabbrizio P., Amadio S., Volont&#xe9; C. Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression. J. Neuroinflamm. 2016;13 doi: 10.1186/s12974-016-0658-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0658-8</ArticleId><ArticleId IdType="pmc">PMC4994328</ArticleId><ArticleId IdType="pubmed">27549088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis K.E., Rasmussen A.L., Bennett W., King A., West A.K., Chung R.S., Chuah M.I. Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: Changes in arginase1 and inducible nitric oxide synthase. J. Neuroinflamm. 2014;11:55. doi: 10.1186/1742-2094-11-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-55</ArticleId><ArticleId IdType="pmc">PMC3994340</ArticleId><ArticleId IdType="pubmed">24655927</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Henkel J.S., Zhao W., Wang J., Huang A., Wen S., Liao B., Appel S.H. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293&#x2013;1314. doi: 10.1093/brain/awr074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr074</ArticleId><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Prado L.D.G.R., Rocha N.P., De Souza L.C., Bicalho I.C.S., Gomez R.S., Vidigal-Lopes M., Braz N.F.T., Vieira &#xc9;.L.M., Teixeira A.L. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 2018;394:69&#x2013;74. doi: 10.1016/j.jns.2018.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.08.033</ArticleId><ArticleId IdType="pubmed">30219498</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Henderson R.D. Effects of gender in amyotrophic lateral sclerosis. Gend. Med. 2010;7:557&#x2013;570. doi: 10.1016/j.genm.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink J., B&#xe4;r P., Joosten E., Otten M., Wokke J., Berg L.V.D. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul. Disord. 2003;13:737&#x2013;743. doi: 10.1016/S0960-8966(03)00104-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-8966(03)00104-4</ArticleId><ArticleId IdType="pubmed">14561497</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J.L., Younkin L.H., Gonzales V., Fadale D.J., Slunt H.H., Lester H.A., Younkin S.G., Borchelt D.R. Rodent A&#x3b2; Modulates the Solubility and Distribution of Amyloid Deposits in Transgenic Mice. J. Biol. Chem. 2007;282:22707&#x2013;22720. doi: 10.1074/jbc.M611050200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M611050200</ArticleId><ArticleId IdType="pmc">PMC4435736</ArticleId><ArticleId IdType="pubmed">17556372</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Cheng X., Zhong S., Zhang X., Liu C., Liu F., Zhao C. Peripheral and Central Nervous System Immune Response Crosstalk in Amyotrophic Lateral Sclerosis. Front. Neurosci. 2020;14:575. doi: 10.3389/fnins.2020.00575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00575</ArticleId><ArticleId IdType="pmc">PMC7308438</ArticleId><ArticleId IdType="pubmed">32612503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgomori T., Yamasaki R., Takeuchi H., Kadomatsu K., Jinno S., Kira J.-I. Differential activation of neuronal and glial STAT3 in the spinal cord of theSOD1G93Amouse model of amyotrophic lateral sclerosis. Eur. J. Neurosci. 2017;46:2001&#x2013;2014. doi: 10.1111/ejn.13650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.13650</ArticleId><ArticleId IdType="pubmed">28715117</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkelmann T., Schemmert S., Honold D., Teichmann K., Butzk&#xfc;ven E., DeMuth H.-U., Shah N.J., Langen K.-J., Kutzsche J., Willbold D., et al. Comprehensive Characterization of the Pyroglutamate Amyloid-&#x3b2; Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice. J. Alzheimer&#x2019;s Dis. 2018;63:115&#x2013;130. doi: 10.3233/JAD-170775.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170775</ArticleId><ArticleId IdType="pmc">PMC5900553</ArticleId><ArticleId IdType="pubmed">29578479</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers D.C., Fisher E.M.C., Brown S.D.M., Peters J., Hunter A.J., Martin J.E. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm. Genome. 1997;8:711&#x2013;713. doi: 10.1007/s003359900551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s003359900551</ArticleId><ArticleId IdType="pubmed">9321461</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers D.C., Peters J., Martin J.E., Ball S., Nicholson S.J., Witherden A.S., Hafezparast M., Latcham J., Robinson T.L., Quilter C.A., et al. SHIRPA, a protocol for behavioral assessment: Validation for longitudinal study of neurological dysfunction in mice. Neurosci. Lett. 2001;306:89&#x2013;92. doi: 10.1016/S0304-3940(01)01885-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)01885-7</ArticleId><ArticleId IdType="pubmed">11403965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa N., Hirose Y., Ohara S., Ono T., Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 1985;50:435&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">3878557</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramow-Newerly W., Lipina T., Abramow-Newerly M., Kim D., Bechard A.R., Xie G., Clapcote S.J., Roder J.C. Methods to rapidly and accurately screen a large number of ENU mutagenized mice for abnormal motor phenotypes. Amyotroph. Lateral Scler. 2006;7:112&#x2013;118. doi: 10.1080/14660820500443000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820500443000</ArticleId><ArticleId IdType="pubmed">16753976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadros M.A., Harris B.M., Anderson W.B., Brichta A.M., Graham B.A., Callister R.J. Are all spinal segments equal: Intrinsic membrane properties of superficial dorsal horn neurons in the developing and mature mouse spinal cord. J. Physiol. 2012;590:2409&#x2013;2425. doi: 10.1113/jphysiol.2012.227389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2012.227389</ArticleId><ArticleId IdType="pmc">PMC3424761</ArticleId><ArticleId IdType="pubmed">22351631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugnot J.-P. Isolate and culture neural stem cells from the mouse adult spinal cord. In: Reynolds B., Deleyrolle L., editors. Neural Progenitor Cells. Methods in Molecular Biology (Methods and Protocols) Volume 1059. Humana Press; Totowa, NJ, USA: 2013. pp. 53&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">23934833</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G., Franklin K.B. Paxinos and Franklin&#x2019;s the Mouse Brain in Stereotaxic Coordinates. Academic Press; Cambridge, MA, USA: 2019.</Citation></Reference><Reference><Citation>McQuin C., Goodman A., Chernyshev V., Kamentsky L., Cimini B.A., Karhohs K.W., Doan M., Ding L., Rafelski S.M., Thirstrup D., et al. CellProfiler 3.0: Next-generation image processing for biology. PLoS Biol. 2018;16:e2005970. doi: 10.1371/journal.pbio.2005970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.2005970</ArticleId><ArticleId IdType="pmc">PMC6029841</ArticleId><ArticleId IdType="pubmed">29969450</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark R.A., Shoaib M., Hewitt K.N., Stanford S.C., Bate S.T. A comparison of InVivoStat with other statistical software packages for analysis of data generated from animal experiments. J. Psychopharmacol. 2012;26:1136&#x2013;1142. doi: 10.1177/0269881111420313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881111420313</ArticleId><ArticleId IdType="pubmed">22071578</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>